TEMOZOLOMIDE & BCNU FOR ANAPLASTIC GLIOMAS

替莫唑胺

• 批准号: 6303480
• 负责人: HARRY S GREENBERG
• 金额: $ 0.02万
• 依托单位: UNIVERSITY OF MICHIGAN AT ANN ARBOR
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6303480
• 关键词: astrocytoma; carmustine; clinical research; combination chemotherapy; glioma; human subject; human therapy evaluation; neoplasm /cancer chemotherapy; temozolomide

The purpose of this study is to determine how patients with brain tumors respond to the combination of the chemotherapy drugs temozolomide and BCNU, and how long their response lasts when treated with this combination. If this treatment works, it may cause your tumor to shrink and prolong your life and/or improve the quality of your life. We also want to find out what kind of side effects these drugs cause in combination and how often they occur. Patients with glioblastoma multiforme, a type of malignant glioma, must have failed treatment with surgery and radiation and may or may not have chemotherapy. Patients with anaplastic glioma must not have had postoperative treatment with radiation or chemotherapy. Patients will receive treatments every six weeks and will be followed with MRI scans for response determination.

这项研究的目的是确定脑肿瘤患者对化疗药物替莫唑胺和BCNU的联合治疗的反应，以及这种联合治疗时他们的反应持续多久。如果这种治疗有效，它可能会导致你的肿瘤缩小，延长你的生命和/或提高你的生活质量。我们还想找出这些药物联合使用会导致什么样的副作用，以及它们发生的频率。多形性胶质母细胞瘤是一种恶性胶质瘤，患者一定是手术和放射治疗失败，可能接受化疗，也可能不接受化疗。间变性胶质瘤患者一定没有接受过术后放疗或化疗。患者将每六周接受一次治疗，随后将进行核磁共振扫描以确定反应。